Ivonne Herrera, MD
Rheumatology · Seaford, DENPI 1992856785
Payments from drug & device makers
Across 393 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Mallinckrodt Hospital Products Inc.$841
- Amgen$819
- AstraZeneca$773
- Pfizer$705
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,19493%
- Education$6447%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,387 |
| Johnson & Johnson | 60 | $1,125 |
| Mallinckrodt Hospital Products Inc. | 22 | $841 |
| Amgen(2 entities) | 34 | $819 |
| AstraZeneca(2 entities) | 38 | $773 |
| Pfizer | 37 | $705 |
| Novartis | 22 | $530 |
| GSK | 19 | $431 |
| UCB, Inc. | 16 | $356 |
| Pacira Therapeutics, Inc. | 9 | $349 |
| E.r. Squibb & Sons, L.L.C. | 14 | $271 |
| Janssen Scientific Affairs, LLC | 2 | $247 |
| Lilly USA, LLC | 10 | $191 |
| Radius Health, Inc. | 5 | $115 |
| Genentech USA, Inc. | 6 | $107 |
| Aurinia Pharma U.S., Inc. | 4 | $88 |
| Organon | 5 | $86 |
| Invivyd Inc | 2 | $53 |
| Boehringer Ingelheim | 2 | $47 |
| Merck | 3 | $46 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| Sobi, Inc | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Sanofi | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $24 |
| Medtronic | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
| Orthogenrx Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $390,351 |
| RinvoqUpadacitinib | 39 | $265,065 |
| Humira(Cf) PenAdalimumab | 21 | $220,812 |
| BenlystaBelimumab | 32 | $184,381 |
| Xeljanz XrTofacitinib Citrate | 18 | $119,977 |
| RemicadeInfliximab | 14 | $102,693 |
| Taltz SyringeIxekizumab | 12 | $91,371 |
| ProliaDenosumab | 48 | $86,110 |
| Actemra ActpenTocilizumab | 15 | $81,635 |
| Taltz AutoinjectorIxekizumab | 11 | $76,453 |
| ActemraTocilizumab | 14 | $69,780 |
| Hydroxychloroquine Sulfate | 489 | $25,968 |
| SavellaMilnacipran Hcl | 14 | $12,519 |
| Mycophenolate Mofetil | 53 | $10,184 |
| Pilocarpine Hcl | 75 | $5,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $15 | $390,35111 claims |
| AbbVieRinvoq, Savella | $1,387 | $277,58353 claims |
| GSKBenlysta | $431 | $184,38132 claims |
| Johnson & JohnsonRemicade | $1,125 | $102,69314 claims |
| AmgenProlia | $819 | $86,11048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other rheumatology in Seaford
- Jose PandoLewes$335K
- Lourdes AponteLewes$20K
- Sheerin JavedNewark$13K
- Jinsong ZhangDover$11K
- Philip SchwartzWilmington$10K
- Amy ZhangNewark$8K
- Surjeet DheerDover$7K
- Yvan Maque AcostaDover$5K
- Robert MoyerDover$3K
- Shakaib QureshiWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.